Fresenius Kabi plans to break the ground on the expansion project in 2017 and complete it by the end of 2026.
Melrose Park facility produces generic and sterile injectable pharmaceuticals used in hospitals and clinics across the US.
Under the project, the company will construct multiple new buildings that will be connected to the existing manufacturing facility.
The buildings will feature fully automated aseptic filling lines with modern isolator technology, expanded lyophilization (freeze-drying) capabilities and formulation areas.
The project will also include the development of warehouse for raw materials, as well as components and an administration building with conference center, laboratories, office space and cafeteria.
Fresenius Kabi operates around 70 manufacturing facilities across the globe.
Fresenius Kabi North America pharmaceuticals division global operations senior vice president Steven Nowicki said: “We are creating a state-of-the-art pharmaceutical manufacturing campus that will be a showcase for our company and the production of injectable generic medicines.
“This project will create many opportunities for our employees, who work around-the-clock to produce life-saving medicines for patients who need them.”
Illinois Governor Bruce Rauner said: “Fresenius Kabi is a leader in pharmaceutical manufacturing and its investment reinforces Illinois’ position as a hub for life sciences and biotechnology.”
Image: The current entrance to Fresenius Kabi's pharmaceutical manufacturing location in Melrose Park, Illinois. Photo: courtesy of Business Wire.